Clinical Trials
49 trialsInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Hoosier Cancer Research Network
Pan Tumor Rollover Study
Bristol-Myers Squibb
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
AndroMETa-CRC
AbbVie
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
CANTOR
AstraZeneca
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
BeOne Medicines
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CLEAR-02
Fudan University
New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
The First Hospital of Jilin University
GRACIE
UNICANCER
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory Study
Ningbo Medical Center Lihuili Hospital
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
FRUITFUL
SCRI Development Innovations, LLC
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Massachusetts General Hospital
PANCREAS
Medical College of Wisconsin
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
PANC
Medical College of Wisconsin
CEIL
Sun Yat-sen University
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
Nizhny Novgorod Regional Clinical Oncology Center
2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
Emory University
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
SWOG Cancer Research Network
BIG
GERCOR - Multidisciplinary Oncology Cooperative Group
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
Fudan University
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
OPTICAL-2
Sun Yat-sen University
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
City of Hope Medical Center
SAIB
First Affiliated Hospital of Zhejiang University
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Sun Yat-sen University
NICER
Baylor College of Medicine
CONVERSION
University of Saskatchewan
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
West China Hospital
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Fudan University
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Akeso
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
Hebei Medical University Fourth Hospital
TORCH-R
Fudan University
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
First Affiliated Hospital of Zhejiang University
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
Fudan University
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
RECTUM2015
Lithuanian University of Health Sciences